Ceride Therapeutics Co., Ltd.
C4U and Celide Therapeutics sign joint research agreement to realize hematopoietic stem cell gene therapy products
……
C4U Co., Ltd. (Headquarters: Suita City, Osaka Prefecture,
Representative Director: Akimitsu Hirai) and Ceride Therapeutics Co., Ltd. (Headquarters: Bunkyo-ku, Tokyo, Representative Director: Nobuyuki Arakawa) have concluded a joint research agreement. To do. In this research, we will perform functional verification in vitro and in vivo (animal experiments) of genetically modified human
hematopoietic stem cells that combine C4U’s CRISPR-Cas3 gene editing technology and Cereide Therapeutics’ human hematopoietic stem cell expansion technology. to hold. Through this research, which combines the domestically produced technologies of both companies, we will strive to deliver therapeutic drugs to patients suffering from genetic diseases as soon as possible.
-C4U overview-
Using the novel genome editing technology CRISPR-Cas3, C4U is promoting the development of new treatments for various diseases including genetic diseases through our own company and in
collaboration with other companies, and at the same time, we are promoting the development of new treatments for various diseases including genetic diseases. We are working on developing a platform for
CRISPR-Cas3 technology was developed based on the research results of C4U’s founding members, Professor Satoshi Mashita of the Department of Advanced Animal Genome Research at the Institute of Medical Science, the University of Tokyo, and visiting Professor Junji Takeda of the Institute of Microbial Diseases, Osaka University. It has features such as low off-target mutations and high safety, and the ability to broadly delete the target gene and its surroundings, and is not affected by the complicated patent situation of CRISPR-Cas9, which is currently being researched all over the world. It is attracting attention as a promising genome editing technology that can counter this.
-Celeide Therapeutics Overview-
Ceride Therapeutics is a company that conducts research and
development of regenerative medicine products that utilize
hematopoietic stem cells, the source of human blood, to help treat intractable blood diseases and genetic diseases, including blood cancer. is. Treatment of intractable blood diseases such as blood cancer requires transplantation of a certain amount of hematopoietic stem cells for complete cure, but by safely and efficiently increasing these hematopoietic stem cells, we are developing next-generation regenerative medicine products. We aim to provide society with the following.
-Contact information regarding this matter-
C4U Co., Ltd.
Head office location: 2-8 Yamadaoka, Suita City, Osaka Prefecture TEL: 06-6369-7180 / E-mail: info@crispr4u.com
URL: https://www.crispr4u.jp/
Ceride Therapeutics Co., Ltd.
Head office location: Entrepreneur Lab, South Research Building, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo
TEL: 050-3612-7767／E-mail: contact@celaidtx.com
URL: https://celaidtx.com/
More details about this release:
https://prtimes.jp/main/html/rd/p/000000006.000100408.html